Validates Manus as a medical device company allowing the Company to fully engage in commercial activities Edinburgh, UK – 17 June 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has received ISO 13485:2016 certification following an assessment of its Quality Management System (“QMS”), validating the … Read more
Edinburgh, UK – 20 April 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, has received £600,000 grant funding from Innovate UK, to optimise and validate the NeuroMotor PenTM (NMP) for screening of dementias and cognitive impairment, over a two-year project. Only around 68% of over 65s, estimated to … Read more
Manus Neurodynamica Limited Ex-Siemens Business Development Manager joins Manus Director of Commercial Growth appointed to execute sales and marketing strategy Edinburgh, UK – 18 March 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Euan Donald as Director of Commercial Growth with immediate effect, where … Read more
Edinburgh, UK – 16 February 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the results of a clinical study to validate the Manus system’s ability to distinguish Parkinson’s Disease (PD) from other movement disorders. The study was conducted at Northumbria Healthcare NHS Foundation Trust, North Shields, UK, … Read more
Edinburgh, UK – 1 February 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the results of a clinical study to evaluate the utility of the Manus system in the assessment of the extrapyramidal adverse effects of antipsychotic drugs conducted in collaboration with The University of Edinburgh and … Read more
Edinburgh, UK – Monday 25th January 2021: Edinburgh medtech company Manus Neurodynamica Limited (“Manus”), has closed a £1.2M funding round to support the launch of its digital pen which provides an early warning of Parkinson’s disease and other neurological conditions. With this latest funding secured, Manus is rolling-out its NeuroMotor PenTM later this year, initially focusing … Read more
Manus Neurodynamica Limited £750,000 investment in Parkinson’s diagnostic Scottish funds to support commercial roll-out of NeuroMotor PenTM Edinburgh, UK – 3 June 2020: Manus Neurodynamica Limited (“Manus”), which develops and markets products for neuromotor assessment, including the NeuroMotor PenTM– a platform technology that can diagnose Parkinson’s disease and other movement disorders, announces it has closed … Read more
Manus Neurodynamica Limited Writing instrument giant STABILO to make Manus’ diagnostic pen Edinburgh, UK – 18th January 2020: MANUS Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces a five-year manufacturing and supply agreement with STABILO International GmbH (“STABILO”) for its digital pen. STABILO will manufacture the pens and ensure … Read more
SBRI Healthcare Development Contract for Parkinson’s diagnostic pen for GPs MANUS Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has received an SBRI Healthcare Development Contract to develop its Parkinson’s disease diagnostic for the GP market. Manus will work with clinicians and NHS Health economists to further develop … Read more